Cargando…
Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer
OBJECTIVE: The purpose of this study was to investigate the effect and influencing factors of post-surgical radioactive iodine (RAI) therapy for patients with low- and intermediate-risk differentiated thyroid cancer (DTC). SUBJECTS AND METHODS: A retrospective analysis of 423 low- and intermediate-r...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Endocrinologia e Metabologia
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689029/ https://www.ncbi.nlm.nih.gov/pubmed/36651706 http://dx.doi.org/10.20945/2359-3997000000538 |
_version_ | 1785152283875475456 |
---|---|
author | Gao, Haiyan Huang, Jiyuan Dai, Qingjing Su, Juan |
author_facet | Gao, Haiyan Huang, Jiyuan Dai, Qingjing Su, Juan |
author_sort | Gao, Haiyan |
collection | PubMed |
description | OBJECTIVE: The purpose of this study was to investigate the effect and influencing factors of post-surgical radioactive iodine (RAI) therapy for patients with low- and intermediate-risk differentiated thyroid cancer (DTC). SUBJECTS AND METHODS: A retrospective analysis of 423 low- and intermediate-risk DTC patients admitted to the Department of Nuclear Medicine, Sichuan Provincial People’s Hospital from January 2005 to December 2020 was performed. All patients were treated with surgery, had a postoperative pathological diagnosis, and were treated with RAI, including 89 males and 334 females. Recurrence risk stratification: 143 cases were low-risk, and 280 cases were intermediate-risk. RESULTS: The excellent response (ER) rate for low- and intermediate-risk were 93.7% and 78.2%, respectively (P < 0.05). There were significant differences in age, cumulative dose of [(131)I], and pretreatment stimulated-Tg (pre-Tg) levels between the low- and intermediate-risk groups (P < 0.05). There were significant differences in the cumulative dose of (131)I and pre-Tg levels between ER and the non-ER group (P < 0.05). The area under the curve (AUC) values were 0.799 in the low-risk group, and 0.747 in the intermediate-risk group for the ROC curve by ER status of pre-Tg. The ER rate with RAI treatment decreased with an increase in pre-Tg levels. CONCLUSION: Pre-Tg was an important factor for RAI treatment decision-making and prognostic evaluation and differed between low-risk and intermediate-risk DTC. Aggressive RAI therapy was recommended for low-risk DTC with pre-Tg ≥ 20.0 ng/mL and in intermediate-risk group with pre-Tg ≥ 10.0 ng/mL. |
format | Online Article Text |
id | pubmed-10689029 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Sociedade Brasileira de Endocrinologia e Metabologia |
record_format | MEDLINE/PubMed |
spelling | pubmed-106890292023-12-01 Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer Gao, Haiyan Huang, Jiyuan Dai, Qingjing Su, Juan Arch Endocrinol Metab Original Article OBJECTIVE: The purpose of this study was to investigate the effect and influencing factors of post-surgical radioactive iodine (RAI) therapy for patients with low- and intermediate-risk differentiated thyroid cancer (DTC). SUBJECTS AND METHODS: A retrospective analysis of 423 low- and intermediate-risk DTC patients admitted to the Department of Nuclear Medicine, Sichuan Provincial People’s Hospital from January 2005 to December 2020 was performed. All patients were treated with surgery, had a postoperative pathological diagnosis, and were treated with RAI, including 89 males and 334 females. Recurrence risk stratification: 143 cases were low-risk, and 280 cases were intermediate-risk. RESULTS: The excellent response (ER) rate for low- and intermediate-risk were 93.7% and 78.2%, respectively (P < 0.05). There were significant differences in age, cumulative dose of [(131)I], and pretreatment stimulated-Tg (pre-Tg) levels between the low- and intermediate-risk groups (P < 0.05). There were significant differences in the cumulative dose of (131)I and pre-Tg levels between ER and the non-ER group (P < 0.05). The area under the curve (AUC) values were 0.799 in the low-risk group, and 0.747 in the intermediate-risk group for the ROC curve by ER status of pre-Tg. The ER rate with RAI treatment decreased with an increase in pre-Tg levels. CONCLUSION: Pre-Tg was an important factor for RAI treatment decision-making and prognostic evaluation and differed between low-risk and intermediate-risk DTC. Aggressive RAI therapy was recommended for low-risk DTC with pre-Tg ≥ 20.0 ng/mL and in intermediate-risk group with pre-Tg ≥ 10.0 ng/mL. Sociedade Brasileira de Endocrinologia e Metabologia 2023-01-17 /pmc/articles/PMC10689029/ /pubmed/36651706 http://dx.doi.org/10.20945/2359-3997000000538 Text en https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Gao, Haiyan Huang, Jiyuan Dai, Qingjing Su, Juan Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer |
title | Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer |
title_full | Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer |
title_fullStr | Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer |
title_full_unstemmed | Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer |
title_short | Radioiodine (131I) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer |
title_sort | radioiodine (131i) treatment decision-making for low- and intermediate-risk differentiated thyroid cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689029/ https://www.ncbi.nlm.nih.gov/pubmed/36651706 http://dx.doi.org/10.20945/2359-3997000000538 |
work_keys_str_mv | AT gaohaiyan radioiodine131itreatmentdecisionmakingforlowandintermediateriskdifferentiatedthyroidcancer AT huangjiyuan radioiodine131itreatmentdecisionmakingforlowandintermediateriskdifferentiatedthyroidcancer AT daiqingjing radioiodine131itreatmentdecisionmakingforlowandintermediateriskdifferentiatedthyroidcancer AT sujuan radioiodine131itreatmentdecisionmakingforlowandintermediateriskdifferentiatedthyroidcancer |